Extragenital Mycoplasma hominis infection following obinutuzumab therapy in a patient with chronic lymphocytic leukemia. (PubMed, IDCases) - Sep 19, 2026 - "Such infections have been reported primarily in patients receiving rituximab; however, they have not been previously described with obinutuzumab therapy...Antimicrobial therapy was transitioned to levofloxacin and doxycycline, which were administered for six weeks with good tolerance and sustained clinical improvement...Because M. hominis lacks a cell wall, routine diagnostic methods and empiric β-lactam therapy may be ineffective, resulting in diagnostic delays. Awareness of this organism and early consideration of targeted therapy are critical to improving outcomes in immunocompromised patients."
Journal • Chronic Lymphocytic Leukemia • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Lymphoma • Musculoskeletal Pain • Non-Hodgkin's Lymphoma • Oncology • Pain • Rheumatology • Small Lymphocytic Lymphoma
|
|
Katherine Benandi; Lucas S Blanton
|